Overview

Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Status:
Not yet recruiting

Trial end date:
2025-04-01

Target enrollment:

Participant gender:

Summary

To evaluate the dose-limiting toxicity of mitoxantrone hydrochloride liposome combined with capecitabine in patients with HER-2 negative advanced breast cancer who have received at least first-line treatment, explore the maximum tolerated dose (MTD) of mitoxantrone hydrochloride liposome, and determine the recommended phase II dose (RP2D).

Phase:

N/A

Details

Lead Sponsor:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborator:

CSPC Ouyi Pharmaceutical Co., Ltd.

Treatments:

Capecitabine
Mitoxantrone